Skip to main content
CONTEC MEDICAL SYSTEMS CO., LTD. logo

CONTEC MEDICAL SYSTEMS CO., LTD. — Investor Relations & Filings

Ticker · 300869 ISIN · CNE1000047F0 LEI · 6556007SL3V6YKCWVA55 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 789 across all filing types
Latest filing 2020-07-30 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 300869

About CONTEC MEDICAL SYSTEMS CO., LTD.

https://www.contecmed.com.cn

CONTEC Medical Systems Co., Ltd. focuses on the research, development, manufacturing, and distribution of medical electronic instruments. The product portfolio encompasses a wide range of diagnostic and monitoring solutions, including pulse oximeters, blood pressure monitors, electrocardiographs, ultrasound equipment, and multi-parameter patient monitors. Additionally, the company provides specialized devices such as fetal monitors, sleep apnea screening systems, and biochemical analyzers. By leveraging integrated research and large-scale production facilities, the organization delivers medical technology designed for clinical, hospital, and home healthcare environments. The company emphasizes technical innovation and adheres to international quality standards to ensure the precision and reliability of its medical hardware and software solutions.

Recent filings

Filing Released Lang Actions
2020年1-6月财务报表及审阅报告
Interim / Quarterly Report Classification · 95% confidence The document is titled as "财务报表及审阅报告 2020 年 1 月 1 日至 6 月 30 日止期间" which translates to "Financial Statements and Review Report for the period January 1, 2020 to June 30, 2020." It contains detailed financial statements including consolidated and company balance sheets, profit and loss statements, cash flow statements, changes in shareholders' equity, and notes to the financial statements. The presence of an "审阅报告" (review report) issued by an accounting firm (Deloitte) indicates this is a reviewed interim financial report rather than a full audit. The period covered is half a year (January to June 2020), which is consistent with an interim or quarterly report. The document is comprehensive and contains actual financial data and analysis, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2020
2020-07-30 Chinese
2017年-2019年财务报表及审计报告
Audit Report / Information Classification · 95% confidence The document is titled as "财务报表及审计报告" which translates to "Financial Statements and Audit Report" for the years 2017, 2018, and 2019. It contains detailed financial statements including consolidated and company balance sheets, profit and loss statements, cash flow statements, and notes to the financial statements. It also includes a full audit report with auditor's opinion, basis for opinion, key audit matters, and responsibilities of management and auditors. The document length is substantial (15,000 characters) and contains actual financial data and analysis, not just an announcement or certification. Therefore, this is a full audit report combined with financial statements, which fits the category of Audit Report / Information (AR). It is not an Annual Report (10-K) because it lacks broader company activity and management discussion sections typical of annual reports, and it is not just an announcement or certification. Hence, the classification is AR with high confidence. FY 2019
2020-07-30 Chinese
首次公开发行股票并在创业板上市发行安排及初步询价公告
Capital/Financing Update Classification · 100% confidence The document is a detailed announcement regarding the initial public offering (IPO) of 康泰医学系统（秦皇岛）股份有限公司 on the Shenzhen Stock Exchange's Growth Enterprise Market (创业板). It includes extensive information about the issuance arrangement, preliminary inquiry, pricing, subscription procedures, investor qualifications, allotment principles, lock-up periods, and timelines for the IPO process. The document references regulatory approvals from the China Securities Regulatory Commission (CSRC) and Shenzhen Stock Exchange rules, and it outlines the underwriting and sponsorship arrangements. The content is focused on the issuance and offering process of new shares, including strategic placement, online and offline subscription, and related investor education and risk disclosures. This type of document is a capital market announcement related to fundraising and issuance activities, not a financial report, management change, or earnings release. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail confirm it is not a brief announcement or a report publication notice, but a substantive issuance announcement.
2020-07-30 Chinese
董事会有关本次发行并上市的决议
Board/Management Information Classification · 95% confidence The document is a resolution from the company's board of directors meeting, detailing decisions about the company's initial public offering (IPO) and listing on the Shenzhen Stock Exchange's Growth Enterprise Market (创业板). It includes approval of the stock issuance plan, authorization for the board to handle IPO-related matters, investment projects funded by the IPO proceeds, profit distribution plans, stock price stabilization measures, and election of board members. The document is a formal board meeting resolution, not a full financial report or earnings release. It is not a shareholder meeting presentation or voting result announcement but a board management decision document. Therefore, it fits best under 'Board/Management Information (MANG)' as it announces changes and decisions by the board of directors.
2020-07-30 Chinese
控股股东、实际控制人对招股说明书的确认意见
Regulatory Filings Classification · 100% confidence The document text contains only a placeholder for an omitted picture and has a true document length of 53 characters, indicating it is extremely short and contains no substantive content or financial data. There is no indication of any report, announcement, or detailed information. Given the lack of content, this document does not fit any specific report category and defaults to the fallback category for miscellaneous filings.
2020-07-30 Chinese
北京市中伦律师事务所关于公司首次公开发行股票并在创业板上市的补充法律意见书（四）
Regulatory Filings Classification · 95% confidence The document is a detailed legal opinion letter issued by a law firm regarding the initial public offering (IPO) and listing of 康泰医学系统（秦皇岛）股份有限公司 on the ChiNext board. It includes extensive legal verification and updates on the company's financial indicators, shareholder changes, business scope changes, related party transactions, and major asset changes. The document references multiple prior legal opinion letters and audit reports, and it serves as a supplementary legal opinion to those prior documents. It is not a financial report, earnings release, or management discussion, but a legal opinion related to the IPO process and compliance. Such legal opinion letters are typically part of regulatory filings related to securities issuance and listing. Given the nature of the document as a legal opinion letter supplementing IPO documentation, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories and includes legal opinions related to securities issuance.
2020-07-30 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.